|
|
||||||||
1 Neurology Service, Veterans Affairs Medical Center, East Orange 07018; and 2 Department of Neurosciences and 3 Pharmacology and Physiology, New Jersey Medical School, Newark, New Jersey 07103
| |
ABSTRACT |
|---|
|
|
|---|
The brain has evolved mechanisms for sensing and regulating glucose metabolism. It receives neural inputs from glucosensors in the periphery but also contains neurons that directly sense changes in glucose levels by using glucose as a signal to alter their firing rate. Glucose-responsive (GR) neurons increase and glucose-sensitive (GS) decrease their firing rate when brain glucose levels rise. GR neurons use an ATP-sensitive K+ channel to regulate their firing. The mechanism regulating GS firing is less certain. Both GR and GS neurons respond to, and participate in, the changes in food intake, sympathoadrenal activity, and energy expenditure produced by extremes of hyper- and hypoglycemia. It is less certain that they respond to the small swings in plasma glucose required for the more physiological regulation of energy homeostasis. Both obesity and diabetes are associated with several alterations in brain glucose sensing. In rats with diet-induced obesity and hyperinsulinemia, GR neurons are hyporesponsive to glucose. Insulin-dependent diabetic rats also have abnormalities of GR neurons and neurotransmitter systems potentially involved in glucose sensing. Thus the challenge for the future is to define the role of brain glucose sensing in the physiological regulation of energy balance and in the pathophysiology of obesity and diabetes.
insulin; food intake; sulfonylureas; ATP-sensitive K+ channel; neuropeptide Y; diet-induced obesity; autonomic nervous system; sympathetic nervous system; parasympathetic nervous system; ventromedial hypothalamus; paraventricular hypothalamus; arcuate nucleus; hypoglycemia
| |
INTRODUCTION |
|---|
|
|
|---|
IT IS CLEAR THAT THE BRAIN both monitors and regulates the energy needs of the body. What is less clear is the way in which the periphery signals its energy needs to the brain. We now know that both carbohydrate and adipose stores are monitored by the brain using combinations of metabolic and neural signals from the periphery. These signals enter the brain and trigger neuroendocrine and autonomic responses that maintain energy homeostasis over a fairly wide variety of environmental perturbations. However, in the highly interconnected conditions of obesity and non-insulin-dependent diabetes mellitus (NIDDM), there appear to be major resettings of normal homeostatic mechanisms. In particular, the brain's ability to monitor and respond to alterations in glucose metabolism becomes aberrant in both individuals predisposed to become obese (obesity prone) and those already obese and diabetic. Such dysregulation also occurs in insulin-dependent diabetes mellitus (IDDM). Whereas much is known about the way in which the brain senses glucose, much remains to be learned about the way in which this information is used to regulate energy homeostasis under physiological circumstances. This review is intended to bring the reader up to date with what is known and act as a potential stimulus for future research into the rapidly expanding field.
Of all the macronutrients, the brain must maintain carbohydrate metabolism within narrow boundaries over short time frames because it uses glucose as a primary fuel and carbohydrate stores are extremely limited (102). The brain monitors plasma glucose levels by both direct (3, 81) and indirect means (30). Oomura et al. (81) and Anand et al. (3) identified neurons within areas of the lateral hypothalamus (LH) and ventromedial hypothalamus (VMH) that altered their firing rates when plasma glucose levels changed. These areas were explored first because of their proposed roles as "feeding" and "satiety" centers (105), respectively, making it logical that they might monitor peripheral glucose levels as a means of controlling ingestion (70). Later, Oomura et al. (82) showed that directly applied glucose altered the firing rate of select neurons. They defined "glucose-responsive" (GR) neurons as those that increased and "glucose-sensitive" (GS) neurons as those that decreased their firing rates when ambient glucose levels rose. In areas such as the LH, VMH, and nucleus of the solitary tract, 20-40% of neurons sampled show such glucose-sensing properties (36, 72, 83, 100). However, there are other brain areas not thought to be involved in ingestive behavior that also contain glucose-sensing neurons and/or neurons with the potential machinery to sense glucose.
On the basis of observations that changes in glucose use affected ingestion, Mayer (70) proposed the glucostatic hypothesis (70) whereby glucose-sensing neurons participated in the short-term regulation of energy intake. Later, Louis-Sylvestre and Le Magnen (65) found that 6-8% dips in plasma glucose were associated with meal initiation. Certainly large reductions in plasma glucose levels or glucose availability can stimulate food intake (86). But to date, it remains uncertain whether the brain can actually detect small changes in plasma glucose or if this might be a primary stimulant of meal initiation. However, central neurons do respond to larger changes in peripheral glucose levels transmitted from portal vein glucosensors by direct neural inputs (30) and by a direct action of glucose that enters the brain by a transport-mediated process (111). Most brain glucose is used primarily as substrate for the energy needs of neurons and glia and does not alter the firing rate of the majority of neurons. However, the fact that a small group of neurons within brain areas tied to neuroendocrine and autonomic control systems uses glucose as a signal to alter their firing rate suggests that such neurons might be intimately involved in energy homeostasis.
| |
ANATOMY AND PHYSIOLOGY OF GLUCOSE-SENSING NEURONS |
|---|
|
|
|---|
GR
neurons.
GR neurons are illustrated in Fig. 1. These
neurons increase their firing rate when ambient glucose levels rise and
cease firing when glucose is removed (82). This response is modulated
by a K+ channel that is sensitive
to the intracellular ratio of ATP to ADP. Thus it is called the
ATP-sensitive K+ channel
(KATP) (109). The
KATP channel is inactivated by
direct binding of ATP, whereas phosphorylation of the channel increases its activity (89). This channel was first identified in pancreatic
-cells where binding of ATP derived from intracellular glucose metabolism inactivates (closes) the channel. This increases
intracellular K+, resulting in
Ca2+ influx,
cellular depolarization, and insulin release (109). The
KATP channel is actually a
functional unit composed of a pore-forming unit (Kir6.2) for
K+ (109) and a binding site for
sulfonylureas, a class of insulin secretogogues. The Kir6.2
pore-forming unit is a member of the inwardly rectifying
K+ channel family (32, 96). The
sulfonylurea receptor (SUR) is a member of the ATP-binding cassette
family and is essential for KATP
channel function (32). As with ATP derived from intracellular glucose
metabolism, occupation of the SUR inactivates the channel and
stimulates insulin secretion. Conversely, drugs known as the K+ channel openers have the
opposite effect. They open the
KATP channel causing
K+ efflux, cellular
hyperpolarization, and prevention of insulin secretion (29).
|
In addition to the pancreatic
-cell the
KATP channel resides on smooth and
cardiac muscles and other nonneural tissues. The KATP channel is present on brain
GR neurons but not glia (20). The Kir6.2 pore-forming unit (20, 32, 35,
63) and both a high (SUR1)- and low (SUR2)-affinity form of the SUR
have been cloned and identified in brain (21, 33, 49, 51, 63, 114). A
presumptive endogenous ligand for the SUR,
-endosulfine, was also
identified in the brain (84) but little is known about its regulation
or regional distribution. Similar to the pancreatic
-cell, the
KATP channel on GR neurons is
inactivated by an increased intracellular ATP-to-ADP ratio or the
presence of sulfonylureas. This leads to accumulation of intracellular
K+ with subsequent membrane
depolarization and cell firing (6, 21, 87, 89). Although it is clear
that GR neurons use glucose as a signaling molecule acting via the
KATP channel, several unresolved issues remain. First, the neuronal glucose transporter (GLUT-3) (26)
and hexokinase (hexokinase I) (64) have Michaelis constant (Km) values
that make them unlikely to be rate limiting for intracellular ATP
production from glucose at the low interstitial glucose concentrations (<2 mM) found in brain under basal conditions (100). Both GLUT-2 (34,
46, 76) and the insulin-sensitive GLUT-4 (45) transporters are also
found in the brain on neurons and/or glia. Although both have
Km values within
the physiological range for brain glucose, they have not been localized
definitively on GR neurons. Glucokinase, which acts as a gatekeeper in
pancreatic
-cells to regulate the rate of ATP production from
glycolysis (69), has also been demonstrated in brain (34, 76). But its
apparent distribution and low abundance leaves open the question of
whether it could serve the same purpose in brain GR neurons. In
addition, intracellular ATP and ADP are highly buffered within the cell
(16). Thus it is unclear how relatively small changes (<1 mM) in
extracellular glucose concentrations might effect a sufficient
alteration in cytoplasmic ATP-to-ADP ratio to regulate the activity of
the KATP channel that is embedded in the plasma membrane. Finally, both SUR1 and Kir6.2 have an anatomic
distribution and abundance in the brain that far outstrips the
estimated number and apparently highly localized distribution of GR
neurons (20, 35).
To explain these discrepancies, we propose that the KATP channel would serve a glucose sensing function only in those neurons that also contain a glucose transporter and/or glucokinase, or an as yet undiscovered hexokinase, with Km values within the physiological range of brain glucose levels (Fig. 1). Such a hexokinase should be localized within the plasma membrane, near the KATP channel, to raise local concentrations of ATP derived from glycolysis directly at the channel (66). This microenvironment could provide sufficiently high levels of ATP/ADP at the KATP channel to regulate its function independent of the general pool of ATP derived from mitochondrial oxidative phosphorylation. In the large population of brain neurons that contain the KATP channel but not the appropriate hexokinase or glucose transporter, the KATP channel would function solely in a neuroprotective role. Thus when either oxygen or glucose became limiting during cerebral anoxia or severe hypoglycemia, intracellular ATP levels would fall. This would activate the KATP channel, causing egress of intracellular K+ and neuronal hyperpolarization. This would antagonize the excitatory toxicity of glutamate released under such circumstances.
Both high-affinity SUR binding sites (21, 49, 51, 74) and the message for the high-affinity SUR1 and the Kir6.2 pore-forming unit (20, 35) are widely distributed throughout the brain. However, brain sites that are critically integrated into pathways regulating autonomic function, metabolism, and energy balance contain a relative paucity of high-affinity SUR binding sites (21, 49, 51). On the other hand, low-affinity SUR binding sites make up ~20-40% of total binding sites in these areas (49, 51). This matches the proportion of GR neurons that are present in these same brain areas (100). Because selective destruction of neuronal cell bodies in such areas abolishes low- but not high-affinity SUR binding, we have proposed that the low-affinity SUR site is located on neuronal cell bodies (21). This low-affinity site should be the SUR2, and we have now used in situ hybridization to show that SUR2 mRNA is localized in these same areas and in the same relative abundance as low-affinity SUR sites (unpublished data).
At least some high-affinity SUR sites appear to be located on GABA (20-22) and glutamate (44) nerve terminals. Raising ambient glucose concentrations at these terminals causes them to release their transmitters. On the other hand, both dopamine (63) and norepinephrine neurons (31) are GR with regard to cell firing rate, but their terminals do not appear to contain the KATP channel (21). Areas such as the substantia nigra contain both dopamine neurons with cell body KATP channels (63) and axon terminals of GABA neurons, which also contain both the Kir6.2 and the high- and low-affinity SUR binding sites (20, 22, 56). Raising ambient glucose levels or infusion of the sulfonylurea glyburide releases the inhibitory transmitter GABA (22), and this opposes the direct action of glucose on the KATP channel to stimulate firing of nigral dopamine neurons (56, 63). The resultant firing rate of nigral dopamine neurons thus becomes highly dependent on ambient glucose concentrations. At lower concentrations, transient stimulation of dopamine neuron firing prevails, whereas at higher concentrations, GABA-induced inhibition predominates (56). Similarly, one might predict that low concentrations of sulfonylureas would stimulate GABA release by acting on the high-affinity SUR1 site, whereas higher concentrations should act at the low-affinity SUR2 site to stimulate firing of the dopamine cell body directly. Similar interactions can be expected in any area that contains both neuronal cell bodies and axon terminals of neurotransmitter neurons that contain a full complement of GR mechanisms.
Finally, there are probably several types of GR neurons that differ in their firing characteristics, conductances, and sensitivities to glucose, sulfonylureas, and/or ATP (89, 98, 100). In a given population, individual neurons may contain different proportions of the SUR1, SUR2, and Kir6.2 units of the KATP channel (63). Some of the observed differences in glucose responsiveness may also be due to the fact that there are various subconductances of the KATP channel. Thus the conductance of an individual channel on a given neuron may vary from moment to moment depending on ambient conditions (89).
GR neurons have several transmitter/peptide phenotypes. Dopamine (20),
norepinephrine (20), GABA (20), and glutamate neurons (43) all express
the KATP channel. In the
hypothalamic arcuate nucleus (Arc), several neurons also express Kir6.2
(20). Arc neurons also contain a functional
KATP channel (Fig.
2). Of particular interest are those Arc
neurons that coexpress both the
KATP channel and neuropeptide Y
(NPY) (20). These neurons exemplify a class of neurons that are
potentially capable of monitoring and integrating a multitude of
metabolic and neural signals from both the periphery and brain. Arc NPY
neurons express not only Kir6.2 (20) but also leptin receptors (28) and
possibly insulin receptors (67). A functional relationship is suggested
by the fact that GR neurons from this area of the hypothalamus are
hyperpolarized by the actions of both leptin (103) and insulin (90) on
the KATP channel. Arc NPY neurons
project to the hypothalamic paraventricular nucleus (PVN), which is
linked to both neuroendocrine and autonomic efferent pathways (7).
Central NPY injections induce a host of anabolic events, including
increased food intake (104) and food-induced insulin release (110),
decreased brown adipose thermogenic capacity (27), and a shift from
lipid to carbohydrate oxidation (11). Restriction of energy intake (15)
and glucoprivation (2) both increase NPY expression selectively in Arc
NPY neurons. This supports the idea that they are specialized to
respond to alterations in energy availability. Hypothalamic
glucose-sensing neurons, including those in the Arc (9), also respond
to a host of neurotransmitters and peptides, including monoamines (38), GABA (38), vasopressin, and oxytocin (37). Thus numerous intrinsic and
extrinsic signals related to energy homeostasis converge on cells such
as the Arc NPY neurons where they are integrated and passed on to
downstream effector areas responsible for energy intake, expenditure,
and storage. It is highly likely that there are many other types of
such integrator neurons throughout the brain that can monitor multiple
metabolic signals and participate in the regulation of energy
homeostasis.
|
GS neurons. These neurons respond to increasing glucose levels by decreasing their firing rate. Whereas they have been characterized electrophysiologically, less is known of the mechanism(s) regulating their firing. Oomura et al. (83) proposed that GS activity is regulated by the Na+-K+-ATP pump (83). Unfortunately, there are no markers for GS neurons comparable to the KATP channel in GR neurons that allow direct characterization of their location and phenotype. Increased c-Fos expression is seen within several hypothalamic, amygdalar, and brain stem areas involved in autonomic activity when glucopenia is induced (80, 85). Although this is an indirect index of neuronal activation, it does not necessarily mean such neurons are GS, merely that they are in the pathway of neurons activated by glucoprivation. On the other hand, direct electrophysiological measurement of firing rate during local glucoprivation has identified GS neurons in areas such as the LH (5) and amygdala (75). GS neurons also receive inputs from peripheral glucose-sensing afferents (99). Besides their direct activation by reduced glucose availability, GS neurons in these areas can also be conditioned to respond to food-related cues independent of ambient glucose levels (5, 75). Finally, these areas are integrated into circuits known to mediate the affective and reward components of ingestion with those that modulate its metabolic effects (40, 41). Thus GS neurons may represent an important interface between systems controlling the affective and metabolic component of energy homeostasis (Fig. 2).
| |
ROLE OF GLUCOSE-SENSING NEURONS IN ENERGY BALANCE |
|---|
|
|
|---|
There is little question that the brain senses and responds to excessively high and low levels of plasma glucose. However, it has been much more difficult to show that glucose levels within the physiological range are used by the brain to regulate energy balance. Alterations in plasma glucose of 2 mM alter brain glucose levels by 0.2-0.3 mM within 10 min, and this is associated with changes in firing of glucose-sensing neurons (100). But these levels are still far greater than the <0.5 mM changes in plasma glucose postulated to trigger meal initiation (65). Whereas both the LH feeding and VMH satiety centers (105) contain relatively high proportions of GS and GR neurons, respectively (5, 100), there is no convincing evidence that alterations in glucose availability in either area can initiate or terminate meals. Intraportal (8) and intracerebroventricular (18) glucose infusions produce small but significant reductions in food intake but it is unclear whether such infusions are within the physiological range.
On the other hand, neurons in the VMH and LH, as well as other hypothalamic areas involved in autonomic regulation are definitely activated in response to both severe hypo- and hyperglycemia (3, 36, 81). Relatively large intravenous or intracarotid glucose infusions produce generalized sympathetic nervous system activation in some humans (92) and animals (47, 48, 58-60) and this can be independent of changes in plasma insulin levels (47, 59). Selective increases in sympathetic nerve activity in thermogenic tissues such as brown adipose depots can be elicited by intracarotid (95), intracerebroventricular (42), and direct glucose infusions into the PVN (94) and VMH (93) (but see Ref. 12). This might underlie the increased energy expenditure produced by an oral glucose load (101). Similarly, intravenous (78) or intracarotid (77) glucose infusions variably increase parasympathetic (vagal) output to the pancreas and liver. Local infusion of glucose into the LH but not VMH increases vagal output to the pancreas (79). Again, there is the question of the physiological relevance of such studies compared with the changes in brain glucose that follow food intake, the usual physiological cause of increased plasma glucose levels.
Similar issues arise when trying to evaluate the role of small changes in plasma and brain glucose in modulating physiological functions. Both peripheral (25) and central glucoprivation (86) stimulate food intake. But the stimuli for this are far outside the usual variations in plasma glucose postulated to initiate ingestion (65). Similarly, systemic, intracerebroventricular (23), and local LH (but not VMH) glucopenia (24) reduce neural activity to brown adipose, suggesting that glucopenia might reduce energy expenditure. Importantly, the brain detects and responds to severe glucoprivation by mounting a neuroendocrine counterregulatory response that mobilizes remaining glucose stores. This response can be mimicked by infusion of 2-deoxyglucose into the VMH (14). On the other hand, either VMH lesions (13) or VMH glucose infusions (12) prevent the counterregulatory response to systemic hypoglycemia. This implicates the VMH as critical to this response. The LH (113) and brain stem (19) also appear to be important for such responses.
Glucose-modulated receptor binding. By
as yet unknown means, changes in plasma glucose are paralleled by
alterations in ligand binding to a variety of receptors in the brain.
For example,
2-adrenoceptor binding in various forebrain areas shows a positive correlation with
plasma glucose levels across a physiological range of 3-14 mM (4,
57). A similar correlation with plasma glucose levels (and with
2-adrenoceptor binding) also
occurs with binding to a class of putative anorectic receptors in the
brain (4). Finally, binding to low-, but not high-affinity SUR sites is
reduced in select forebrain areas by only 1 h of intracarotid glucose
infusions (51). This latter phenomenon suggests that relatively
short-term changes in glucose levels can alter the function of the
glucose-sensing mechanism (KATP
channel) that allow GR neurons to sense glucose. These changes can be
mimicked in vitro with glucose concentrations from 0 to 10 mM (51).
Again, the mechanism for such changes is unknown but could be related
to changes in the phosphorylation state of the receptors induced by
intracellular glucose metabolism.
| |
BRAIN GLUCOSE SENSING IN OBESITY AND DIABETES |
|---|
|
|
|---|
Obesity and NIDDM. In rodent models, obesity and NIDDM are inextricably linked because of the presence of hyperinsulinemia and insulin resistance (58, 61). There is also a very high incidence of NIDDM in obese humans (107). Thus it is often difficult to separate the effects of hyperinsulinemia from those related to other metabolic aspects of obesity when assessing brain function in these cases. This is important because insulin affects KATP channel function (90) as well as transmitter and peptide systems that could indirectly alter channel function (55, 97).
We have used the rat model of diet-induced obesity (DIO) to investigate abnormalities of glucose regulation in obesity. When outbred rats are fed a diet moderately high in calorie, fat, and sucrose content, one-half develop DIO and the rest are diet-resistant (DR), gaining no more carcass fat than controls fed a low-fat diet (58, 60, 62). Inbreeding studies suggest that this is a polygenic trait, similar to some human obesities (53). DIO rats have reduced sympathetic input to their pancreas (62) but have an exaggerated sympathetic response to both intravenous (58, 60) and intracarotid glucose infusions (48). By contrast, intracarotid glucose infusions selectively increase c-Fos expression in neurons of the VMN, PVN, and Arc only in DR rats (54). This apparent paradox can be explained by postulating that glucose-induced activation of forebrain GR neurons normally inhibits, whereas glucose-induced inhibition of GS neurons normally increases, sympathetic activity. Thus increased forebrain glucose levels would have no effect on sympathetic activity in DR rats because of simultaneous activation of GR neurons and inhibition of GS neurons. But in obesity-prone rats, sympathetic stimulation would occur because of their impaired activation of inhibitory GR neurons, whereas GS neurons were normally inactivated.
DIO rats also exhibit several other signs of reduced central glucose
sensitivity. They do not upregulate forebrain
2-adrenoceptor binding normally
to increased plasma glucose levels (57). Obesity-prone rats have
reduced or absent low-affinity SUR binding throughout their forebrains
(49) and do not downregulate these few receptors normally to raised
glucose levels (51). Finally, VMH neurons in obesity-prone rats have
defective KATP channel sensitivity to both ATP and sulfonylureas (88). Interestingly, obese Zucker (fa/fa)
rats have no identifiable VMH KATP
channel (91). Thus reduced central sensitivity to glucose may be a
predisposing factor to the development of increased metabolic
efficiency and obesity when obesity-prone rats are exposed to a
high-energy diet.
Arc NPY neurons may be a potential link between such defective glucose
sensing and the development of DIO. Arc neurons have a functional
KATP channel (Fig.
3) and are activated by raising forebrain
glucose levels in DR but not DIO rats (54). Although Arc NPY neurons do
express Kir6.2 (20) and have glucose-induced increases in c-Fos
expression (54), they have not directly been shown to be GR. Somewhat
paradoxically, both fasting (52) and glucopenia increase NPY (2),
whereas glucopenia increases c-Fos expression in these neurons (71).
The failure of DIO Arc neurons to respond to altered glucose levels
might contribute to the basal overexpression and failure to increase
NPY message in energy-restricted obesity-prone rats (52). A similar
dysregulation of Arc NPY occurs in both obese Zucker
(fa/fa)
rats (10) and
ob/ob
mice (106). Such dysregulation of glucose-modulated NPY expression may
contribute to the propensity of such animals to become obese when the
caloric density and dietary fat content is increased.
|
IDDM. As with NIDDM, IDDM also profoundly affects brain glucose sensing and other systems that modulate its glucose sensing capabilities. Streptozotocin-induced IDDM decreases brain glucose uptake (73), increases hexokinase activity in areas such as the PVN (39), and produces major alterations in both high- and low-affinity SUR binding (50). Hyperglycemia in insulin-deficient diabetic (BB) or streptozotocin-treated or Wistar fatty rats is associated with increased Arc NPY expression (1, 112). This overexpression occurs even when hyperglycemia is not associated with insulin deficiency (68). On the other hand, insulin itself inhibits NPY upregulation during energy restriction (97). Thus there is a complex interaction between glucose and insulin in the regulation of Arc NPY and energy metabolism in IDDM.
Finally, tight control of patients with IDDM is associated with repeated episodes of hypoglycemia and this leads to defective brain glucose sensing. Even a single bout of hypoglycemia reduces both the awareness of and the counterregulatory response to hypoglycemia (17). In rats, there is a similar attenuation of the sympathoadrenal counterregulatory response in some but not all rats subjected to repeated bouts of hypoglycemia (108). Preliminary data (N. Tkacs, personal communication) suggest that this depressed counterregulatory response can be reproduced by central infusions of 2-deoxyglucose, suggesting that impairment of brain glucose-sensing function is responsible for this defect.
| |
SUMMARY AND CONCLUSIONS |
|---|
|
|
|---|
The brain has evolved mechanisms for sensing the energy needs of the body. Because plasma glucose levels change more rapidly than most signals that reflect the body's metabolic status and because the brain is dependent on a constant supply of glucose for its energy needs, it has a vested interest in maintaining glucose levels within a fairly narrow range. Although the brain may be able to sense and respond to elevated postingestive glucose levels or to reduced levels seen during iatrogenically induced hypoglycemia, it is less clear how brain glucose sensing might affect other facets of energy intake, expenditure, and storage. Moreover, there are a number of abnormalities in brain glucose-sensing neurons, the transmitters and peptides that affect them, and the physiological responses to changes in glucose levels that occur in both obesity and diabetes. But there is as yet no direct link established between these defects of glucose sensing and the pathophysiology of obesity and diabetes. However, we now have many of the tools needed to increase our knowledge of these critical issues affecting energy homeostasis.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: B. E. Levin, Neurology Service (127C), VA Medical Center, E. Orange, NJ 07018-1095 (E-mail: levin{at}umdnj.edu).
| |
REFERENCES |
|---|
|
|
|---|
1.
Abe, M.,
M. Saito,
H. Ikeda,
and
T. Shimazu.
Increased neuropeptide Y content in the arcuato-paraventricular hypothalamic neuronal system in both insulin-dependent and non-insulin-dependent diabetic rats.
Brain Res.
539:
223-227,
1991[Medline].
2.
Akabayashi, A.,
C. T. Zaia,
I. Silva,
H. J. Chae,
and
S. F. Leibowitz.
Neuropeptide Y in the arcuate nucleus is modulated by alterations in glucose utilization.
Brain Res.
621:
343-348,
1993[Medline].
3.
Anand, B. K.,
G. S. Chhina,
K. N. Sharma,
S. Dua,
and
B. Singh.
Activity of single neurons in the hypothalamus feeding centers: effect of glucose.
Am. J. Physiol.
207:
1146-1154,
1964.
4.
Angel, I.,
and
M.-A. Taranger.
Coupling between hypothalamic
2-adrenoceptors and [3H]mazindol binding sites in response to several hyperglycemic stimuli in mice.
Brain Res.
490:
367-372,
1991.
5.
Aou, S.,
Y. Oomura,
L. Lenard,
H. Nishino,
A. Inokuchi,
T. Minami,
and
H. Y. Misaki.
Behavioral significance of monkey hypothalamic glucose-sensitive neurons.
Brain Res.
302:
69-74,
1984[Medline].
6.
Ashford, M. L. J.,
P. R. Boden,
and
J. M. Treherne.
Tolbutamide excites rat glucoreceptive ventromedial hypothalamic neurones by indirect inhibition of ATP-K+ channels.
Br. J. Pharmacol.
101:
531-540,
1990[Medline].
7.
Bai, F. L.,
M. Yamano,
Y. Shiotani,
P. C. Emson,
A. D. Smith,
J. F. Powell,
and
M. Tohyama.
An arcuato-paraventricular and dorsomedial hypothalamic neuropeptide Y containing system which lacks norepinephrine in the rat.
Brain Res.
331:
172-175,
1985[Medline].
8.
Baird, J. P.,
H. J. Grill,
and
J. M. Kaplan.
Intake suppression after hepatic portal glucose infusion: all-or-none effect and its temporal threshold.
Am. J. Physiol.
272 (Regulatory Integrative Comp. Physiol. 41):
R1454-R1460,
1997
9.
Baker, R. A.,
M. Herkenham,
and
L. S. Brady.
Effects of long-term treatment with antidepressant drugs on proopiomelanocortin and neuropeptide Y mRNA expression in the hypothalamic arcuate nucleus in rats.
J. Neuroendocrinol.
8:
337-343,
1996[Medline].
10.
Beck, B.,
A. Burlet,
J.-P. Nicolas,
and
C. Burlet.
Unexpected regulation of hypothalamic neuropeptide Y by food deprivation and refeeding in the Zucker rat.
Life Sci.
50:
923-930,
1992[Medline].
11.
Billington, C. J.,
J. E. Briggs,
S. Harker,
M. Grace,
and
A. S. Levine.
Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism.
Am. J. Physiol.
266 (Regulatory Integrative Comp. Physiol. 35):
R1765-R1770,
1994
12.
Borg, M. A.,
R. S. Sherwin,
W. P. Borg,
W. V. Tamborlane,
and
G. I. Shulman.
Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats.
J. Clin. Invest.
99:
361-365,
1997[Medline].
13.
Borg, W. P.,
M. J. During,
R. S. Sherwin,
M. A. Borg,
M. L. Brines,
and
G. I. Shulman.
Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia.
J. Clin. Invest.
93:
1677-1682,
1994.
14.
Borg, W. P.,
R. S. Sherwin,
M. J. During,
M. A. Borg,
and
G. I. Shulman.
Local ventromedial hypothalamic glucopenia triggers counterregulatory hormone release.
Diabetes
44:
180-184,
1995[Abstract].
15.
Brady, L. S.,
M. A. Smith,
P. W. Gold,
and
M. Herkenham.
Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats.
Neuroendocrinology
52:
441-447,
1990[Medline].
16.
Cesar, M. D. C.,
and
J. E. Wilson.
Further studies on the coupling of mitochondrially bound hexokinase to intramitochondrially compartmented ATP generated by oxidative phosphorylation.
Arch. Biochem. Biophys.
350:
109-117,
1998[Medline].
17.
Dagogo-Jack, S.,
C. Rattarasarn,
and
P. E. Cryer.
Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM.
Diabetes
43:
1426-1434,
1994[Abstract].
18.
Davis, J. D.,
D. Wirtshafter,
K. E. Asin,
and
D. Brief.
Sustained intracerebroventricular infusion of brain fuels reduces body weight and food intake in rats.
Science
212:
81-83,
1981
19.
DiRocco, R. J.,
and
H. J. Grill.
The forebrain is not essential for sympathoadrenal hyperglycemic response to glucoprivation.
Science
204:
1112-1114,
1979
20.
Dunn-Meynell, A. A.,
N. E. Rawson,
and
B. E. Levin.
Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain.
Brain Res.
814:
41-54,
1998[Medline].
21.
Dunn-Meynell, A. A.,
V. H. Routh,
J. J. McArdle,
and
B. E. Levin.
Low affinity sulfonylurea binding sites reside on neuronal cell bodies in the brain.
Brain Res.
745:
1-9,
1997[Medline].
22.
During, M. J.,
P. Leone,
K. E. Davis,
D. Kerr,
and
R. S. Sherwin.
Glucose modulates rat substantia nigra GABA release in vivo via ATP-sensitive potassium channels.
J. Clin. Invest.
95:
2403-2408,
1995.
23.
Egawa, M.,
H. Yoshimatsu,
and
G. A. Bray.
Effects of 2-deoxy-D-glucose on sympathetic nerve activity to interscapular brown adipose tissue.
Am. J. Physiol.
257 (Regulatory Integrative Comp. Physiol. 26):
R1377-R1385,
1989
24.
Egawa, M.,
H. Yoshimatsu,
and
G. A. Bray.
Lateral hypothalamic injection of 2-deoxy-D-glucose suppresses sympathetic activity.
Am. J. Physiol.
257 (Regulatory Integrative Comp. Physiol. 26):
R1386-R1392,
1989
25.
Friedman, M. I.,
M. G. Tordoff,
and
I. Ramirez.
Integrated metabolic control of food intake.
Brain Res. Bull.
17:
855-859,
1986[Medline].
26.
Gerhart, D. A.,
M. A. Broderius,
and
N. D. D. L. R. Borson.
Neurons and microvessels express the brain glucose transporter GLUT3.
Proc. Natl. Acad. Sci. USA
89:
733-737,
1992
27.
Giraudo, S. Q.,
C. M. Kotz,
M. K. Grace,
A. S. Levine,
and
C. J. Billington.
Rat hypothalamic NPY mRNA and brown fat uncoupling protein mRNA after high-carbohydrate or high-fat diets.
Am. J. Physiol.
266 (Regulatory Integrative Comp. Physiol. 35):
R1578-R1583,
1994
28.
Hakansson, M.-L.,
H. Brown,
N. Ghilardi,
R. C. Skoda,
and
B. Meister.
Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus.
J. Neurosci.
18:
559-572,
1998
29.
Hausser, M. A.,
J. R. de Weille,
and
M. Lazdunski.
Activation by cromakalim of pre- and post-synaptic ATP-sensitive K+ channels in substantia nigra.
Biochem. Biophys. Res. Commun.
174:
909-914,
1991[Medline].
30.
Hevener, A. L.,
R. N. Bergman,
and
C. M. Donovan.
Novel glucosensor for hypoglycemic detection localized to the portal vein.
Diabetes
46:
1521-1525,
1997[Abstract].
31.
Illes, P.,
J. Sevcik,
E. P. Finta,
R. Frolich,
K. Nieber,
and
W. Norenberg.
Modulation of locus coeruleus neurons by extra- and intracellular adenosine 5'-triphosphate.
Brain Res. Bull.
35:
513-519,
1994[Medline].
32.
Inagaki, N.,
T. Gonoi,
J. P. Clement IV,
N. Namba,
J. Inazawa,
G. Gonzalez,
L. Aguilar-Bryan,
S. Seino,
and
J. Bryan.
Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.
Science
270:
1166-1170,
1995
33.
Inagaki, N.,
T. Gonoi,
J. P. Clement,
C. Z. Wang,
L. Aguilar-Bryan,
J. Bryan,
and
S. Seino.
A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels.
Neuron
16:
1101-1107,
1996.
34.
Jetton, T. L.,
Y. Liang,
C. C. Pettepher,
E. C. Zimmerman,
F. G. Cox,
K. Horvath,
F. M. Matschinsky,
and
M. A. Magnuson.
Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut.
J. Biol. Chem.
269:
3641-3654,
1994
35.
Karschin, C.,
C. Ecke,
F. M. Ashcroft,
and
A. Karschin.
Overlapping distribution of KATP channel-forming unit Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain.
FEBS Lett.
401:
59-64,
1997[Medline].
36.
Kow, L.-M.,
and
D. W. Pfaff.
Actions of feeding-relevant agents on hypothalamic glucose-responsive neurons in vitro.
Brain Res. Bull.
15:
509-513,
1985[Medline].
37.
Kow, L.-M.,
and
D. W. Pfaff.
Vasopressin excites ventromedial hypothalamic glucose-responsive neurons in vitro.
Physiol. Behav.
37:
153-158,
1986[Medline].
38.
Kow, L.-M.,
and
D. W. Pfaff.
Responses of hypothalamic paraventricular neurons in vitro to norepinephrine and other feeding-relevant agents.
Physiol. Behav.
46:
265-271,
1989[Medline].
39.
Krukoff, T. L.,
and
K. P. Patel.
Alterations in brain hexokinase activity associated with streptozotocin-induced diabetes mellitus in the rat.
Brain Res.
522:
157-160,
1990[Medline].
40.
Larsen, P. J.,
A. Hay-Schmidt,
and
J. D. Mikkelsen.
Efferent connections from the lateral hypothalamic region and the lateral preoptic area to the hypothalamic paraventricular nucleus of the rat.
J. Comp. Neurol.
342:
299-319,
1994[Medline].
41.
LeDoux, J. E.,
J. Iwata,
P. Cicchetti,
and
D. J. Reis.
Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear.
J. Neurosci.
8:
2517-2529,
1988[Abstract].
42.
Le Feuvre, R. A.,
A. J. Woods,
M. J. Stock,
and
N. J. Rothwell.
Effects of central injection of glucose on thermogenesis in normal, VMH-lesioned and genetically obese rats.
Brain Res.
547:
110-114,
1991[Medline].
43.
Lee, K.,
A. K. Dixon,
I. C. Rowe,
M. L. Ashford,
and
P. J. Richardson.
Direct demonstration of sulphonylurea-sensitive KATP channels on nerve terminals of the rat motor cortex.
Br. J. Pharmacol.
115:
385-387,
1995[Medline].
44.
Lee, K.,
A. K. Dixon,
I. C. M. Rowe,
M. L. J. Ashford,
and
P. J. Richardson.
The high-affinity sulfonylurea receptor regulates KATP channels in nerve terminal of the rat motor cortex.
J. Neurochem.
66:
2562-2571,
1996[Medline].
45.
Leloup, C.,
M. Arluison,
N. Kassis,
N. Lepetit,
N. Cartier,
P. Ferre,
and
L. Penicaud.
Discrete brain areas express the insulin-responsive glucose transporter GLUT4.
Brain Res. Mol. Brain Res.
38:
45-53,
1996[Medline].
46.
Leloup, C.,
M. Arluison,
N. Lepetit,
N. Cartier,
P. Marfaing-Jallat,
P. Ferre,
and
L. Penicaud.
Glucose transporter 2 (GLUT 2): expression in specific brain nuclei.
Brain Res.
638:
221-226,
1994[Medline].
47.
Levin, B. E.
Glucose increases rat plasma norepinephrine levels by direct action on the brain.
Am. J. Physiol.
261 (Regulatory Integrative Comp. Physiol. 30):
R1351-R1357,
1991
48.
Levin, B. E.
Intracarotid glucose-induced norepinephrine response and the development of diet-induced obesity.
Int. J. Obes.
16:
451-457,
1992.
49.
Levin, B. E.,
K. L. Brown,
and
A. A. Dunn-Meynell.
Differential effects of diet and obesity on high and low affinity sulfonylurea binding sites in the rat brain.
Brain Res.
739:
293-300,
1996[Medline].
50.
Levin, B. E.,
and
A. Dunn-Meynell.
Effect of streptozotocin-induced diabetes on rat brain sulfonylurea binding sites.
Brain Res. Bull.
46:
513-518,
1998[Medline].
51.
Levin, B. E.,
and
A. Dunn-Meynell.
In vivo and in vitro regulation of 3H glyburide binding to brain sulfonylurea receptors in obesity-prone and resistant rats by glucose.
Brain Res.
776:
146-153,
1998.
52.
Levin, B. E.,
and
A. A. Dunn-Meynell.
Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats.
Am. J. Physiol.
272 (Regulatory Integrative Comp. Physiol. 41):
R1365-R1370,
1997
53.
Levin, B. E.,
A. A. Dunn-Meynell,
B. Balkan,
and
R. E. Keesey.
Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats.
Am. J. Physiol.
273 (Regulatory Integrative Comp. Physiol. 42):
R725-R730,
1997
54.
Levin, B. E.,
E. K. Govek,
and
A. A. Dunn-Meynell.
Reduced glucose-induced neuronal activation in the hypothalamus of diet-induced obese rats.
Brain Res.
808:
317-319,
1998[Medline].
55.
Levin, B. E.,
P. A. Israel,
and
D. P. Figlewicz Lattemann.
Insulin selectively downregulates
2-adrenoceptors in the arcuate and dorsomedial nucleus.
Brain Res. Bull.
45:
179-181,
1998[Medline].
56.
Levin, B. E.,
R. Levy,
and
E. Govek.
The ATP-sensitive potassium (KATP) channel and glucose-induced nigrostriatal dopamine release.
Soc. Neurosci. Abstr.
23:
576A,
1997.
57.
Levin, B. E.,
and
B. Planas.
Defective glucoregulation of brain
2-adrenoceptors in obesity-prone rats.
Am. J. Physiol.
264 (Regulatory Integrative Comp. Physiol. 33):
R305-R311,
1993
58.
Levin, B. E.,
and
A. C. Sullivan.
Glucose-induced norepinephrine levels and obesity resistance.
Am. J. Physiol.
253 (Regulatory Integrative Comp. Physiol. 22):
R475-R481,
1987
59.
Levin, B. E.,
and
A. C. Sullivan.
Glucose, insulin and sympathoadrenal activation.
J. Auton. Nerv. Syst.
20:
233-242,
1987[Medline].
60.
Levin, B. E.,
and
A. C. Sullivan.
Glucose-induced sympathetic activation in obesity-prone and resistant rats.
Int. J. Obes.
13:
235-246,
1989[Medline].
61.
Levin, B. E.,
J. Triscari,
and
A. C. Sullivan.
Sympathetic activity in thyroid-treated Zucker rats.
Am. J. Physiol.
243 (Regulatory Integrative Comp. Physiol. 12):
R170-R178,
1982.
62.
Levin, B. E.,
J. Triscari,
and
A. C. Sullivan.
Relationship between sympathetic activity and diet-induced obesity in two rat strains.
Am. J. Physiol.
245 (Regulatory Integrative Comp. Physiol. 14):
R367-R371,
1983.
63.
Liss, B.,
R. Bruns,
and
J. Roeper.
Heterogeneous expression of ATP-sensitive potassium channel. Subunits in dopaminergic substantia nigra neurons: a single-cell RT-PCR analysis.
Soc. Neurosci. Abstr.
23:
1739A,
1997.
64.
Liu, F.,
Q. Dong,
A. M. Myers,
and
H. J. Fromm.
Expression of human brain hexokinase in Escherichia coli: purification and characterization of the expressed enzyme.
Biochem. Biophys. Res. Commun.
177:
305-311,
1991[Medline].
65.
Louis-Sylvestre, J., and J. Le Magnen. A fall in blood
glucose level precedes meal onset in free-feeding rats.
Neurosci. Biobehav. Rev.
4, Suppl. 1:
13-15, 1980.
66.
Lynch, R. M.,
R. Mejia,
and
R. S. Balaban.
Energy transduction at the cell plasmalemma: coupling through membrane associated adenosine triphosphate?
Comm. Mol. Cel. Biophys.
5:
151-170,
1988.
67.
Marks, J. L.,
D. Porte, Jr.,
W. L. Stahl,
and
D. G. Baskin.
Localization of insulin receptor mRNA in rat brain by in situ hybridization.
Endocrinology
127:
3234-3236,
1990[Abstract].
68.
Marks, J. L.,
K. Waite,
and
M. Li.
Effects of streptozotocin-induced diabetes mellitus and insulin treatment on neuropeptide Y mRNA in the rat hypothalamus.
Diabetologia
36:
497-502,
1993[Medline].
69.
Matchinsky, F. M.
A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm.
Diabetes
45:
223-241,
1996[Abstract].
70.
Mayer, J.
Regulation of energy intake and the body weight: the glucostatic theory and lipostatic hypothesis.
Ann. NY Acad. Sci.
63:
15-43,
1955.
71.
Minami, S.,
J. Kamegai,
H. Sugihara,
N. Suzuki,
H. Higuchi,
and
I. Wakabayashi.
Central glucoprivation evoked by administration of 2-deoxy-D-glucose induces expression of the c-fos gene in a subpopulation of neuropeptide Y neurons in the rat hypothalamus.
Mol. Brain Res.
33:
305-310,
1995[Medline].
72.
Mizuno, Y.,
and
Y. Oomura.
Glucose responding neurons in the nucleus tractus solitarius of the rat, in vitro study.
Brain Res.
307:
109-116,
1984[Medline].
73.
Mooradian, A. D.,
and
A. M. Morin.
Brain uptake of glucose in diabetes mellitus: the role of glucose transporters.
Am. J. Med. Sci.
301:
173-177,
1991[Medline].
74.
Mourre, C.,
C. Widmann,
and
M. Lazdunski.
Sulfonylurea binding sites associated with ATP-regulated K+ channels in the central nervous system: autoradiographic analysis of their distribution and ontogenesis, and of their localization in mutant mice cerebellum.
Brain Res.
519:
29-43,
1990[Medline].
75.
Nakano, Y.,
Y. Oomura,
L. Lenard,
H. Nishino,
S. Aou,
T. Yamamoto,
and
K. Aoyagi.
Feeding-related activity of glucose- and morphine-sensitive neurons in the monkey amygdala.
Brain Res.
399:
167-172,
1986[Medline].
76.
Navarro, M.,
F. R. de Fonseca,
R. Alvarez-Buylla,
J. A. Chowen,
J. A. Zueco,
R. Gomez,
J. Eng,
and
E. Blazquez.
Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor antagonists as an inhibitory signal for food and water intake.
J. Neurochem.
67:
1982-1991,
1996[Medline].
77.
Niijima, A.
The effect of glucose on the activity of the adrenal nerve and pancreatic branch of the vagus nerve in the rabbit.
Neurosci. Lett.
1:
159-162,
1975.
78.
Niijima, A.
Blood glucose levels modulate efferent activity in the vagal supply to the rat liver.
J. Physiol. (Lond.)
364:
105-112,
1985
79.
Niijima, A.,
H. Kannan,
and
H. Yamashita.
Neural control of blood glucose homeostasis: effect of microinjection of glucose into hypothalamic nuclei on efferent activity of pancreatic branch of vagus nerve in the rat.
Brain Res. Bull.
20:
811-816,
1988[Medline].
80.
Niimi, M.,
M. Sato,
M. Tamaki,
Y. Wada,
J. Takahara,
and
K. Kawanishi.
Induction of Fos protein in the rat hypothalamus elicited by insulin-induced hypoglycemia.
Neurosci. Res.
23:
361-364,
1995[Medline].
81.
Oomura, Y.,
K. Kimura,
H. Ooyama,
T. Maeo,
M. Iki,
and
N. Kuniyoshi.
Reciprocal activities of the ventromedial and lateral hypothalamic area of cats.
Science
143:
484-485,
1964
82.
Oomura, Y.,
T. Ono,
H. Ooyama,
and
M. J. Wayner.
Glucose and osmosensitive neurons of the rat hypothalamus.
Nature
222:
282-284,
1969[Medline].
83.
Oomura, Y.,
H. Ooyama,
M. Sugimori,
T. Nakamura,
and
Y. Yamada.
Glucose inhibition of the glucose-sensitive neurone in the rat lateral hypothalamus.
Nature
247:
284-286,
1974[Medline].
84.
Peyrollier, K.,
L. Heron,
A. Virsolvy-Vergine,
A. Le Cam,
and
D. Bataille.
-Endosulfine is a novel molecule, structurally related to a family of phosphoproteins.
Biochem. Biophys. Res. Commun.
223:
583-586,
1996[Medline].
85.
Ritter, S.,
and
T. T. Dinh.
2-Mercaptoacetate and 2-deoxy-D-glucose induce Fos-like immunoreactivity in rat brain.
Brain Res.
641:
111-120,
1994[Medline].
86.
Ritter, S.,
S. M. Murnane,
and
E. E. Ladenheim.
Glucoprivic feeding is impaired by lateral or fourth ventricular alloxan injection.
Am. J. Physiol.
243 (Regulatory Integrative Comp. Physiol. 12):
R312-R317,
1982
87.
Roper, J.,
and
F. M. Ashcroft.
Metabolic inhibition and low internal ATP activate K-ATP channels in rat dopaminergic substantia nigra neurones.
Pflügers Arch.
430:
44-54,
1995[Medline].
88.
Routh, V. H.,
B. E. Levin,
and
J. J. McArdle.
Defective ATP-sensitive K+ (KATP) channel in ventromedial hypothalamic nucleus (VMN) of obesity-prone (DIO) rats.
FASEB J.
12:
A864,
1998.
89.
Routh, V. H.,
J. J. McArdle,
and
B. E. Levin.
Phosphorylation modulates the activity of the ATP-sensitive K+ channel in the ventromedial hypothalamic nucleus.
Brain Res.
778:
107-119,
1997[Medline].
90.
Routh, V. H.,
J. J. McArdle,
D. C. Spanswick,
B. E. Levin,
and
M. L. J. Ashford.
Insulin modulates the activity of glucose responsive neurons in the ventromedial hypothalamic nucleus (VMN).
Soc. Neurosci. Abstr.
23:
577A,
1997.
91.
Rowe, I. C.,
P. R. Boden,
and
M. L. Ashford.
Potassium channel dysfunction in hypothalamic glucose-receptive neurones of obese Zucker rats.
J. Physiol. (Lond.)
497:
365-377,
1996[Medline].
92.
Rowe, J. W.,
J. B. Young,
K. L. Minaker,
A. L. Stevens,
J. Pallotta,
and
L. Landsberg.
Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.
Diabetes
30:
219-225,
1981[Medline].
93.
Sakaguchi, T.,
and
G. A. Bray.
The effect of intrahypothalamic injections of glucose on sympathetic efferent firing rate.
Brain Res. Bull.
18:
591-595,
1987[Medline].
94.
Sakaguchi, T.,
and
G. A. Bray.
Sympathetic activity following PVN injections of glucose and insulin.
Brain Res. Bull.
21:
25-29,
1988[Medline].
95.
Sakaguchi, T.,
and
G. A. Bray.
Ventromedial hypothalamic lesions attenuate responses of sympathetic nerves to carotid arterial infusions of glucose and insulin.
Int. J. Obes.
14:
127-134,
1990[Medline].
96.
Sakura, H.,
C. Ammala,
P. A. Smith,
P. A. Gribble,
and
F. M. Ashcroft.
Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle.
FEBS Lett.
377:
338-344,
1995[Medline].
97.
Schwartz, M. W.,
A. J. Sipols,
J. L. Marks,
G. Sanacora,
J. D. White,
A. Scheurink,
S. E. Kahn,
D. G. Baskin,
S. C. Woods,
D. P. Figlewicz,
and
D. Porte, Jr.
Inhibition of hypothalamic neuropeptide Y gene expression by insulin.
Endocrinology
130:
3608-3616,
1992[Abstract].
98.
Sellers, A. J.,
P. R. Boden,
and
M. L. J. Ashford.
Lack of effect of potassium channel openers on ATP-modulated potassium channels recorded from rat ventromedial hypothalamic neurones.
Br. J. Pharmacol.
107:
1068-1074,
1992[Medline].
99.
Shimizu, N.,
Y. Oomura,
D. Novin,
C. V. Grijava,
and
P. H. Cooper.
Functional correlations between lateral hypothalamic glucose-sensitive neurons and hepatic portal glucose-sensitive units in rat.
Brain Res.
265:
49-54,
1983[Medline].
100.
Silver, I. A.,
and
M. Erecinska.
Glucose-induced intracellular ion changes in sugar-sensitive hypothalamic neurons.
J. Neurophysiol.
79:
1733-1745,
1998
101.
Simonson, D. C.,
L. Tappy,
E. Jequier,
J. P. Felber,
and
R. A. DeFronzo.
Normalization of carbohydrate-induced thermogenesis by fructose in insulin-resistant states.
Am. J. Physiol.
254 (Endocrinol. Metab. 17):
E201-E207,
1988
102.
Sokoloff, L.,
M. Reivich,
C. Kennedy,
M. H. DesRosiers,
C. S. Patlak,
O. Pettigrew,
O. Sakaruda,
and
M. Shinohara.
The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.
J. Neurochem.
23:
897-916,
1977.
103.
Spanswick, D.,
M. A. Smith,
V. E. Groppi,
S. D. Logan,
and
M. L. Ashford.
Leptin inhibits hypothalamic neurons by activation of ATP- sensitive potassium channels.
Nature
390:
521-525,
1997[Medline].
104.
Stanley, B. G.,
and
S. F. Leibowitz.
Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior.
Proc. Natl. Acad. Sci. USA
82:
3940-3943,
1985
105.
Stellar, E.
The physiology of motivation.
Psychol. Rev.
5:
5-22,
1954.
106.
Stephens, T. W.,
M. Basinski,
P. K. Bristow,
J. M. Bue-Valleskey,
S. G. Burgett,
L. Craft,
J. Hale,
J. Hoffmann,
H. M. Hsiung,
A. Kriauclunas,
W. MacKellar,
P. R. Rosteck, Jr.,
B. Schoner,
D. Smith,
F. C. Tinsley,
X.-Y. Zhang,
and
M. Heiman.
The role of neuropeptide Y in antiobesity action of the obese gene product.
Nature
377:
530-532,
1995[Medline].
107.
Stern, M. P.
Diabetes and cardiovascular disease. The "common soil" hypothesis.
Diabetes
44:
369-374,
1995[Abstract].
108.
Tkacs, N. C.,
and
B. E. Levin.
Reduced counterregulation after repeated insulin injections in rats: CNS activation patterns.
Soc. Neurosci. Abstr.
24:
1121A,
1998.
109.
Trapp, S.,
and
F. M. Ashcroft.
A metabolic sensor in action: news from the ATP-sensitive K+- channel.
News Physiol. Sci.
12:
255-263,
1997.
110.
Van Dijk, G.,
A. E. Bottone,
J. H. Strubbe,
and
A. B. Steffens.
Hormonal and metabolic effects of hypothalamic administration of neuropeptide Y during rest and feeding.
Brain Res.
660:
96-103,
1994[Medline].
111.
Vannucci, S. J.,
F. Maher,
and
I. A. Simpson.
Glucose transporter proteins in brain: delivery of glucose to neurons and glia.
Glia
21:
2-21,
1991.
112.
White, J. D.,
D. Olchovsky,
M. Kershaw,
and
M. Berelowitz.
Increased hypothalamic content of preproneuropeptide-Y messenger ribonucleic acid in streptozotocin-diabetic rats.
Endocrinology
126:
765-772,
1990[Abstract].
113.
Yoshimatsu, H.,
M. Egawa,
and
G. A. Bray.
Adrenal sympathetic nerve activity in response to hypothalamic injections of 2-deoxy-D-glucose.
Am. J. Physiol.
261 (Regulatory Integrative Comp. Physiol. 30):
R875-R881,
1991
114.
Zini, S.,
R. Zini,
and
Y. Ben-Ari.
Nucleotides modulate the low affinity binding sites for [3H]glibenclamide in the rat brain.
J. Pharmacol. Exp. Ther.
264:
701-708,
1993
This article has been cited by other articles:
![]() |
L. Kang, N. M. Sanders, A. A. Dunn-Meynell, L. D. Gaspers, V. H. Routh, A. P. Thomas, and B. E. Levin Prior hypoglycemia enhances glucose responsiveness in some ventromedial hypothalamic glucosensing neurons Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R784 - R792. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Cheng, L. Zhou, W. Zhu, A. Wang, C. Tang, O. Chan, R. S. Sherwin, and R. J. McCrimmon Type 1 corticotropin-releasing factor receptors in the ventromedial hypothalamus promote hypoglycemia-induced hormonal counterregulation Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E705 - E712. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Barnes and J. L. Beverly Nitric oxide's role in glucose homeostasis Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R590 - R591. [Full Text] [PDF] |
||||
![]() |
N. Simler, A. Malgoyre, N. Koulmann, A. Alonso, A. Peinnequin, and A. X. Bigard Hypoxic stimulus alters hypothalamic AMP-activated protein kinase phosphorylation concomitant to hypophagia J Appl Physiol, June 1,&n |